In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $75.16 in the prior trading day, Hologic, Inc (NASDAQ: HOLX) closed at $75.02, down -0.19%. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 2.36 million shares were traded. HOLX stock price reached its highest trading level at $75.127 during the session, while it also had its lowest trading level at $74.99.
Ratios:
Our goal is to gain a better understanding of HOLX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.19. For the most recent quarter (mrq), Quick Ratio is recorded 3.06 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.51.
On January 05, 2026, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $78.
BNP Paribas Exane Downgraded its Outperform to Neutral on November 21, 2025, while the target price for the stock was maintained at $79.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 20 ’25 when Stamoulis Christiana sold 7,402 shares for $73.07 per share. The transaction valued at 540,864 led to the insider holds 47,336 shares of the business.
Stamoulis Christiana bought 7,402 shares of HOLX for $540,864 on Oct 20 ’25. On Sep 22 ’25, another insider, MACMILLAN STEPHEN P, who serves as the Chairman, President and CEO of the company, sold 138,358 shares for $66.97 each. As a result, the insider received 9,266,118 and left with 1,234,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HOLX now has a Market Capitalization of 16734377984 and an Enterprise Value of 17143249920. As of this moment, Hologic,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.21, and their Forward P/E ratio for the next fiscal year is 15.00. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.08 while its Price-to-Book (P/B) ratio in mrq is 3.31. Its current Enterprise Value per Revenue stands at 4.181 whereas that against EBITDA is 12.688.
Stock Price History:
The Beta on a monthly basis for HOLX is 0.72, which has changed by 0.0778718 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, HOLX has reached a high of $75.34, while it has fallen to a 52-week low of $51.90. The 50-Day Moving Average of the stock is 0.46%, while the 200-Day Moving Average is calculated to be 12.05%.
Shares Statistics:
The stock has traded on average 3.52M shares per day over the past 3-months and 2146740 shares per day over the last 10 days, according to various share statistics. A total of 222.56M shares are outstanding, with a floating share count of 219.51M. Insiders hold about 1.60% of the company’s shares, while institutions hold 97.66% stake in the company. Shares short for HOLX as of 1767139200 were 3745780 with a Short Ratio of 1.06, compared to 1764288000 on 4315796. Therefore, it implies a Short% of Shares Outstanding of 3745780 and a Short% of Float of 1.9199998999999999.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 12.0 analysts currently analyzing and rating the stock of Hologic, Inc (HOLX).The consensus estimate for the next quarter is $1.1, with high estimates of $1.14 and low estimates of $1.05.
Analysts are recommending an EPS of between $4.64 and $4.47 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $5.0, with 15.0 analysts recommending between $5.18 and $4.75.
Revenue Estimates
10 analysts predict $1.07B in revenue. The current quarter. It ranges from a high estimate of $1.09B to a low estimate of $1.05B. As of. The current estimate, Hologic, Inc’s year-ago sales were $1.02BFor the next quarter, 10 analysts are estimating revenue of $1.05B. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $1.04B.
A total of 18 analysts have provided revenue estimates for HOLX’s current fiscal year. The highest revenue estimate was $4.32B, while the lowest revenue estimate was $4.24B, resulting in an average revenue estimate of $4.28B. In the same quarter a year ago, actual revenue was $4.1BBased on 16 analysts’ estimates, the company’s revenue will be $4.51B in the next fiscal year. The high estimate is $4.57B and the low estimate is $4.42B.
